Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice.
| Autor: | Gutbrodt KL; Authors' Affiliations: Department of Chemistry and Applied Biosciences, ETH Zürich, Zurich; and., Casi G; Philochem AG, Otelfingen, Switzerland., Neri D; Authors' Affiliations: Department of Chemistry and Applied Biosciences, ETH Zürich, Zurich; and neri@pharma.ethz.ch. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Molecular cancer therapeutics [Mol Cancer Ther] 2014 Jul; Vol. 13 (7), pp. 1772-6. Date of Electronic Publication: 2014 Apr 23. |
| DOI: | 10.1158/1535-7163.MCT-14-0105 |
| Abstrakt: | Antibody-drug conjugates are increasingly being used for cancer therapy, but little is known about their ability to promote anticancer immunity, which may lead to long-lasting remissions. We investigated the therapeutic effect of antibody-based pharmacodelivery of cemadotin, a cytotoxic drug, and IL2, a strong proinflammatory cytokine. Using the F8 antibody, which selectively localizes to the tumor neovasculature, combination treatment led to tumor eradication, in a process dependent on CD8(+) T cells and natural killer cells in the C1498 syngeneic mouse model of acute myelogenous leukemia. The clinical combination of antibody-drug conjugates and antibody-cytokine proteins should be facilitated by their orthogonal toxicity profiles. (©2014 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|